

Original citation:

Wang, Weishan, Yang, Tongjian, Li, Yihong, Li, Shanshan, Yin, Shouliang, Styles, Kathryn, Corre, Christophe and Yang, Keqian. (2016) Development of a synthetic oxytetracycline-inducible expression system for streptomyces using de novo characterized genetic parts. ACS Synthetic Biology .

Permanent WRAP URL:

<http://wrap.warwick.ac.uk/79077>

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

"This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Synthetic Biology, copyright © American Chemical Society after peer review and technical editing by the publisher.

To access the final edited and published work see:

<http://dx.doi.org/10.1021/acssynbio.6b00087> "

A note on versions:

The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP url' above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk

1
2
3
4 **Development of a synthetic oxytetracycline-inducible expression system for**
5
6 **streptomycetes using *de novo* characterized genetic parts**
7

8
9 Weishan Wang^{#,†}, Tongjian Yang^{#,‡}, Yihong Li[†], Shanshan Li[†], Shouliang Yin[†],
10
11 Kathryn Styles[§], Christophe Corre[§], and Keqian Yang^{†,*}
12
13

14
15 [†] State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese
16
17 Academy of Sciences, No.1 West Beichen Road, Chaoyang District, Beijing 100101,
18
19 People's Republic of China
20
21

22
23 [‡] University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing 100049,
24
25 People's Republic of China
26
27

28
29 [§] School of Life Sciences and Department of Chemistry, University of Warwick,
30
31 Coventry CV4 7AL, United Kingdom
32
33

34
35
36
37 [#]W. W. and T. Y. contributed equally to this work.
38
39

40
41 ^{*}Correspondence: Keqian Yang, E-mail: yangkq@im.ac.cn;
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Precise control of gene expression using exogenous factors is of great significance. To develop ideal inducible expression systems for streptomycetes, new genetic parts, oxytetracycline responsive repressor OtrR, operator *otrO* and promoter *otrBp* from *Streptomyces rimosus*, were selected *de novo* and characterized *in vivo* and *in vitro*. OtrR showed strong affinity to *otrO* ($K_D = 1.7 \times 10^{-10}$ M) and oxytetracycline induced dissociation of the OtrR/DNA complex in a concentration-dependent manner. Based on these genetic parts, a synthetic inducible expression system Potr* was optimized. Induction of Potr* with 0.01-4 μ M of oxytetracycline triggered a wide-range expression level of *gfp* reporter gene in different *Streptomyces* species. Benchmarking Potr* against the widely used constitutive promoters *ermE** and *kasOp** revealed greatly enhanced levels of expression when Potr* was fully induced. Finally, Potr* was used as a tool to activate and optimize the expression of the silent jadamycin biosynthetic gene cluster in *Streptomyces venezuelae*. Altogether, the synthetic Potr* presents a new versatile tool for fine-tuning gene expression in streptomycetes.

Keywords

Inducible expression system, streptomycetes, genetic parts, wide-range strength, biosynthetic gene cluster, natural product

Introduction

The Gram-positive streptomycetes are well-known producers of an immense diversity of biologically active compounds, which have been applied in human medicine,

1
2
3 animal health, and plant crop protection ¹. In the past decades, a suite of genetic tools
4 such as plasmids and constitutive promoters have been specifically developed for
5
6 such as plasmids and constitutive promoters have been specifically developed for
7
8 streptomycetes ²⁻⁸. These tools have greatly facilitated genetic manipulations of this
9
10 genus. However, only a limited number of inducible expression systems are available
11
12 for the precise control of gene expression in streptomycetes ⁵.
13
14

15
16 Inducible expression systems are versatile genetic tools for controlling gene
17
18 expression upon induction with chemical or physical inducers, and they are typically
19
20 used for the functional characterization of genes and for the production of medically
21
22 or industrially important proteins ^{9, 10}. In many cases, inducible expression systems
23
24 have also been employed to optimize the levels of pathway expression in order to
25
26 achieve economically viable titers, yields and productivities of products of interest ^{8, 11,}
27
28 ¹². However, the existing inducible expression systems have their limitations and
29
30 could not meet the need of synthetic biology to precise control gene expression in
31
32 streptomycetes. The thiostrepton-inducible *ptipA* was the first inducible expression
33
34 system developed from *Streptomyces lividans* ¹³. It depends on the presence of the
35
36 activator TipAL but also relies on the resistance gene *tsr*, and it often show high level
37
38 of leaky expression ^{14, 15}. Other inducible expression systems developed for
39
40 streptomycetes include the ε-caprolactam-inducible expression system based on the
41
42 nitrilase promoter/operator *PnitA/NitR* from *Rhodococcus rhodochrous* ¹⁶, the
43
44 synthetic tetracycline (Tc)-inducible expression system based on the repressor
45
46 TetR/operator *tetO* from *Escherichia coli* ¹⁷ and the cumate-inducible system from
47
48 *Pseudomonas putida* ¹⁸. While the *PnitA/NitR* inducible expression system is
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 excellent for protein overproduction from high copy number plasmids, it is unclear
5
6 whether this system will also perform well to control expression in routine genetic
7
8 analysis and metabolic pathway engineering¹⁷. Importantly, the inducers
9
10 ϵ -caprolactam and cumate are degradable in some *Streptomyces* species^{16, 19}, which
11
12 will limit their applications. In addition, the above-mentioned genetic parts for
13
14 inducible expression systems are not perfectly compatible in streptomycetes, which
15
16 are characterized by large and high-GC content genomes and intricate regulatory
17
18 networks²⁰. The regulatory networks of streptomycetes result in background noise
19
20 when using these genetic parts^{17, 18}. For example, each streptomycetes genome
21
22 contains over 100 TetR family regulators, and thus TetR homologs SCO0253 perturbs
23
24 the work of the synthetic Tc-inducible expression system developed by TetR
25
26 repressor and *tetO* operator in *Streptomyces coelicolor*¹⁷. Therefore, although several
27
28 inducible expression systems have been reported for streptomycetes¹⁵⁻¹⁸, there is still
29
30 a definitive lack of tightly inducible expression system suitable for elaborate studies
31
32 in streptomycetes.
33
34
35
36
37
38
39
40
41

42 Ideally, an inducible expression system should be completely turned off when
43
44 repressed, and tunable to different strengths when induced. In addition, the inducer
45
46 should be easily available and have little pleiotropic effects on growth⁹. *Streptomyces*
47
48 species exhibit marked regulatory capacity and flexibility²⁰. They typically have
49
50 more than 8000 protein-coding genes, and >10% of the coding genes are predicted to
51
52 be transcription factors²⁰. The native regulators and operators in the genomes of
53
54 streptomycetes are therefore rich repositories of genetic parts that fulfill the
55
56
57
58
59
60

1
2
3 requirements for the development of inducible expression systems.
4
5

6
7 In the present study, we aimed to find unique genetic parts that respond to small
8
9 molecules in streptomycetes and to develop ideal inducible expression systems.
10

11
12 Interestingly, regulatory genes situated in biosynthetic gene clusters (BGCs) that
13
14 direct secondary metabolite biosynthesis do often interact with the products of that
15
16 pathway and regulate the transcription of biosynthetic genes and/or resistance genes
17
18 ^{8,21}. For example, ActR ²², KijA8 ²³, LanK ²⁴, SimR ²⁵, and VarR ²⁶ have all been
19
20 reported to bind the end products or intermediates of the corresponding BGCs and
21
22 induce the expression of divergently adjacent exporter genes. The regulatory
23
24 mechanism is similar to the Tc-inducible repressor (TetR) and exporter (TetA) from
25
26 the *E. coli* transposon Tn10 ²³. The well-characterized repressor TetR and operator
27
28 *tetO* have been widely used as genetic parts to construct inducible expression systems
29
30 in prokaryotes ²⁷, mammalian cells ²⁸ and other organisms (such as *Drosophila* ²⁹).
31
32

33
34 Here we therefore focused on the pairs of antibiotic exporter and regulatory genes
35
36 from BGCs of streptomycetes to identify the candidate genetic parts. By combining
37
38 the rareness of the regulators and the availability of the inducers, the oxytetracycline
39
40 (OTC)-inducible regulator OtrR, operator *otrO* and promoter *otrBp* from
41
42 *Streptomyces rimosus* were selected and characterized *de novo*. Using these
43
44 well-characterized genetic parts, a synthetic and tightly controlled inducible
45
46 expression system Potr* with wide-range OTC-inducible strength was developed.
47
48
49 Potr* showed negligible leaky expression levels in the absence of the inducer OTC
50
51
52 and high levels of induced expression in *Streptomyces venezuelae*, *Streptomyces*
53
54
55
56
57
58
59
60

1
2
3
4 *coelicolor* and *Streptomyces albus*. Furthermore, Potr* was used to activate the silent
5
6 jadomycin BGC and to optimize the production of this antibiotic in *S. venezuelae*
7
8
9 ISP5230, exemplifying the usefulness of this system in eliciting the production of
10
11 silent and possibly cryptic antibiotic-like natural products in streptomycetes.
12

13 14 **Results and Discussion**

15 16 17 **Search for parts in genomes of streptomycetes**

18
19
20 To develop a strict inducible expression system with minimum interference from
21
22 endogenous regulators of streptomycetes, pairs of antibiotic exporter and regulator
23
24 genes in the genomes of streptomycetes were selected to investigate candidate genetic
25
26 parts. For ideal genetic parts, the inducers should be highly stable and easily available.
27
28 Aromatic polyketides, synthesized by type II polyketide synthases in streptomycetes,
29
30 are recalcitrant to be degraded in these producers³⁰. Therefore, we searched all type
31
32 II polyketide BGCs with identified products from the genomes of streptomycetes, and
33
34 extracted sequences of exporters as well as the divergently arranged putative
35
36 regulators (Table 1). The regulators were identified as TetR, ArsR, MarR or DeoR
37
38 family (Table 1). Previous studies have reported that intrinsic large numbers of TetR
39
40 homologs may perturb the inducible expression system developed through other TetR
41
42 family regulators¹⁷, therefore this family regulators were excluded from this study.
43
44
45 Considering the availability and cost of the inducers, we selected genetic parts from
46
47 the commercialized type II polyketide BGCs. Only OTC and chlortetracycline (CTC)
48
49 meet the criteria of being readily available as well as low cost. The putative regulators
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 of OTC and CTC exporters (OtrR and CtcS) belong to MarR family, which have
5
6 many less members (approximate 20-30 members) compared with the TetR family in
7
8 streptomycetes. To avoid the interference of native regulators in streptomycetes, the
9
10 sequences of OtrR and CtcS were used as queries to conduct a BLASTp search
11
12 against the local protein database containing the sequences of 569,791 proteins from
13
14 streptomycetes deposited in UniProt. Highly homologous orthologs of OtrR and CtcS
15
16 (> 30% identities) were not observed in most genomes of streptomycetes, except that
17
18 of their native hosts, *Streptomyces monomycini* and *Streptomyces griseoflavus*. The
19
20 results suggest that OtrR and CtcS are suitable candidates with minimum interference
21
22 from other endogenous regulators in streptomycetes. Since OTC is known to be less
23
24 toxic to microbial cells than CTC, we decided to investigate the regulatory
25
26 mechanism of the OTC exporter to identify inducible genetic parts (Fig. 1).
27
28
29
30
31
32

33 34 **Characterization of the regulatory mechanism of OtrR**

35
36
37 The MarR family transcriptional regulators exist as dimers and bind palindromic
38
39 sequences within target promoters, resulting in either transcriptional repression or
40
41 activation³¹. To confirm the regulatory role of OtrR on the putative target promoter
42
43 *otrBp*, a Lux reporter system was constructed in heterologous host *E. coli* (Fig. 2a).
44
45 The *lux* genes were directly controlled by *otrBp*, endowing the strains with the ability
46
47 of bioluminescence (Fig. 2b). When an OtrR expression plasmid was transferred into
48
49 *E. coli* harboring the *lux* reporter plasmid, the bioluminescence was severely
50
51 repressed (Fig. 2b), indicating that OtrR could repress the expression of *otrBp*.
52
53
54
55 Furthermore, when OTC was added, the bioluminescence was restored in a
56
57
58
59
60

1
2
3
4 dose-dependent manner (Fig. 2b). These results suggest that OtrR can sense and
5
6 respond to OTC to de-repress the transcription of *otrBp*. More importantly, the
7
8 concentration of OTC needed to completely unlock *otrBp* is approximately 2.5 μM ,
9
10 which is a concentration much lower than the minimal inhibitory concentration (MIC,
11
12 approximate 10-30 μM).
13
14

15
16 To further confirm the direct interaction of OtrR with *otrBp*, OtrR was expressed and
17
18 purified from *E. coli* (Supplementary Fig. S1) and an electrophoretic mobility shift
19
20 assay (EMSA) was performed with a probe of *otrBp* (P-*otrB*). As shown in Fig. 2c,
21
22 OtrR could bind P-*otrB* in a concentration-dependent manner. The binding was shown
23
24 to be specific, with no retardation was observed for the negative control probe of *hrdB*
25
26 promoter (P-*hrdB*) (Supplementary Fig. S2). These results demonstrate that OtrR
27
28 represses *otrBp* by direct interaction. The responses of OtrR/P-*otrB* complexes to
29
30 OTC were also analyzed by EMSA *in vitro*. We observed that OtrR and P-*otrB*
31
32 complexes would dissociate in the presence of OTC, and this dissociation effect also
33
34 occurred in an OTC concentration-dependent manner (Fig. 2d). This data along with
35
36 the results obtained from the *in vivo* Lux reporter system undoubtedly indicate that
37
38 OtrR represses the transcription of *otrBp* by direct binding, and OTC releases this
39
40 repression effect by attenuating the binding of OtrR, thus inducing the transcription of
41
42 *otrBp*.
43
44
45
46
47
48
49
50

51 52 **Determination of OtrR operator *otrO* and the core promoter of *otrBp***

53
54
55 To develop a new OTC-inducible expression system, it is necessary to identify the
56
57
58
59
60

1
2
3
4 operator of OtrR. DNase I footprinting was performed to locate the binding sites of
5
6 OtrR in the *otrBp* region using a capillary sequencer. As shown in Fig. 3a, a fully
7
8 protected region was observed in the presence of OtrR, and this region encompasses
9
10 two 6-nt inverted repeats (GACAAG) with 2-bp spacing (Fig. 3b). To further confirm
11
12 whether the identified region containing the palindromic sequence is the operator of
13
14 OtrR (designated as *otrO*), we amplified the probes with (PR) or without (PL) the
15
16 palindromic sequence (Supplementary Fig. S3a) and tested their binding with OtrR by
17
18 EMSA. The results showed that the retardation was only observed with the PR probe
19
20 (Supplementary Fig. S3b and c). Furthermore, the binding ability of the 20-bp probe
21
22 (P20) containing the palindromic sequence with OtrR was examined using EMSA,
23
24 and the retardation was readily detected (Supplementary Fig S3d). These results
25
26 suggest that this palindromic sequence is the core region of *otrO*. To determine the
27
28 equilibrium dissociation constant (K_D) between the interaction of OtrR and *otrO*,
29
30 surface plasmon resonance (SPR) was performed. The sequence containing *otrO* was
31
32 labeled with biotin and immobilized onto a streptavidin sensor chip, and subsequently
33
34 OtrR was injected. The sensorgrams showed increased binding with the increasing
35
36 OtrR concentrations (Fig. 3c). The best fit for OtrR yielded K_D value of 0.17 nM. The
37
38 K_D of interaction between OtrR and *otrO* is similar to that of the interaction between
39
40 Tc-inducible repressor TetR and operator *tetO*, which have been successfully used as
41
42 genetic parts for the development of inducible expression systems and the
43
44 construction of genetic circuits in many organisms²⁷⁻²⁹. Therefore, the new genetic
45
46 parts OtrR and *otrO* show good potential for widespread application. Notably, OtrR,
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 containing only 165 amino acids, is smaller than TetR, which will enable a much
5
6 easier and economical application in other organism. In addition, the operator of OtrR
7
8 is very unique. A search using *otrO* sequence did not give closely matched sequences
9
10 in the genomes of streptomycetes, suggesting that OtrR and *otrO* are ideal parts that
11
12 do not interplay with host DNA or regulators in streptomycetes.
13
14

15
16
17 To determine the loci of the *otrO* relative to the the transcriptional start site (TSS) of
18
19 *otrBp*, rapid amplification of 5'-cDNA ends (5'-RACE) was performed (Fig. 3d).
20

21
22 Then the putative -10 and -35 regions were identified based on the determined TSS
23
24 (Fig. 3d), which shares high nucleotide sequence identity with the core promoter
25
26 recognized by the essential sigma factor HrdB³². After defining the core region of
27
28 *otrBp*, *otrO* site was found to overlap with -35 region of *otrBp* (Fig. 3d).
29
30
31

32 **Development of the OTC-inducible expression system for streptomycetes**

33
34
35 OtrR and *otrBp* were identified from *Streptomyces* species, and thus the native
36
37 *otrR-otrBp* inducible expression system (designated as Potr) should be compatible in
38
39 streptomycetes. The performance of Potr was firstly evaluated in *S. venezuelae*, which
40
41 grows in a diffuse and homogenous manner in a variety of liquid media³³. Such
42
43 growth characteristics facilitate accurate data normalization. Strain *S. venezuelae*
44
45 WVR2006::pIJ-Potr was incubated in MYM medium supplemented with OTC at
46
47 concentrations ranging from 10 nM to 6 μ M. We observed that GFP fluorescence
48
49 increased with increasing concentrations of OTC and Potr was fully induced at 4 μ M
50
51 OTC (Fig. 4a). Surprisingly, the fully induced fluorescence was stronger than that
52
53
54
55
56
57
58
59
60

1
2
3 driven by the widely used constitutive promoters *kasOp**² and *ermEp**³⁴ (Fig. 4b),
4
5 suggesting that the activity of *otrBp* was very strong. Recently, Bai et al.³⁵ has shown
6
7 that *kasOp** exhibited the strongest activity among all the tested constitutive
8
9 promoters in streptomycetes using a flow cytometry-based quantitative method. At the
10
11 fully induced state, we observed that the activity of native *otrBp* was stronger than
12
13 that of *kasOp** (Fig. 4b). Hence, the activity of *otrBp* does not require further
14
15 optimization. However, we observed that the leaky expression without OTC induction
16
17 was higher compared with the control (Fig. 4b). Thus, *Potr* should be engineered to
18
19 reduce leaky expression.
20
21

22
23
24
25
26 Zhang et al.³⁶ reported that the integration of the same operators at two locations,
27
28 flanking the -35 and the -10 regions of the target promoter, can achieve tighter control
29
30 of the promoter activity. To reduce the leaky expression of *Potr*, we engineered the
31
32 inducible expression system (designated as *Potr**) by inserting another operator
33
34 downstream of the TSS of *otrBp* (Fig. 4c). After examining the GFP fluorescence of *S.*
35
36 *venezuelae* WVR2006::pIJ-*Potr** (map of pIJ-*Potr**, see Supplementary Fig. S4), we
37
38 observed that *Potr** showed nearly the same GFP-response curve as *Potr* to OTC (Fig.
39
40 4d), whereas the leaky expression was significantly reduced to a level similar to the
41
42 control (Fig. 4e).
43
44
45
46
47
48

49
50 To examine the activity of *Potr** induced by different doses of OTC at the
51
52 transcription level, real-time quantitative PCR (RT-qPCR) was performed to assess
53
54 the transcript levels of the *gfp* gene in *S. venezuelae* WVR2006::pIJ-*Potr**. The results
55
56 showed that the transcript abundance of *gfp* increased in an OTC
57
58
59
60

1
2
3
4 concentration-dependent manner (Fig. 5a), suggesting that the inducible activity of
5
6 Potr* was sensitively controlled at the transcriptional level in *S. venezuelae*.
7

8
9 To evaluate the growth inhibitory effects by OTC, the growth of *S. venezuelae* was
10
11 assayed in the presence OTC. The results indicate OTC does not have significant
12
13 effects on growth at lower than 6 μM (Supplementary Fig. S5). As a concentration
14
15 less than 4 μM OTC is sufficient to induce Potr or Potr* to a fully expressed level, the
16
17 inducer can be used at a concentration where the growth is hardly affected.
18
19

20 21 22 **Evaluation of the performance of Potr* in different *Streptomyces* species** 23

24
25 To evaluate the inducible behavior of Potr* in other *Streptomyces* species, the
26
27 production of GFP fluorescence under the control of Potr* was further evaluated in *S.*
28
29 *coelicolor* M1146::pIJ-Potr* and *S. albus* J1074::pIJ-Potr*. It was shown that the
30
31 expression of *gfp* was sensitively induced in a OTC concentration-dependent manner
32
33 in the two hosts; the leaky expression of *gfp* was negligible without OTC and the fully
34
35 induced output of *gfp* was much higher than that of the constitutive promoters *kasOp**
36
37 ² and *ermEp**³⁴ (Fig. 5b and c). When grown in liquid culture, *S. coelicolor* and *S.*
38
39 *albus* form large pellets or clumps, meaning that the GFP fluorescence assay might
40
41 have margins of error in the data normalization of these strains. Therefore, we further
42
43 performed RT-qPCR to more accurately evaluate the transcription levels of *gfp*
44
45 reporter gene in *S. coelicolor* M1146::pIJ-Potr* and *S. albus* J1074::pIJ-Potr* after
46
47 induction using different OTC concentrations. The results showed that the transcript
48
49 levels of the *gfp* gene also increased in an OTC concentration-dependent manner in
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the two *Streptomyces* strains (Fig. 5d and e), consistent with the results obtained in *S.*
4
5
6 *venezuelae*. The highly consistent results generated in different *Streptomyces* species
7
8 indicate that Potr* is a tightly controlled inducible expression system with wide-range
9
10 strength in streptomycetes.
11
12

13 14 **Application of Potr* in activation and optimization of the silent jadomycin BGC** 15

16
17 The potential for the production of high-value secondary metabolites is even larger
18
19 than previously realized in streptomycetes²¹. However, accessing this rich resource to
20
21 identify new compounds through the activation of cryptic pathways is still a challenge.
22
23 We hypothesized that a cryptic gene cluster under the control of an inducible
24
25 expression system will facilitate the identification of corresponding product, as the
26
27 production will increase with the inducer in a concentration-dependent manner. To
28
29 demonstrate this application, we designed a plug-and-play plasmid pIW01
30
31 (Supplementary Fig. S6) using the newly developed inducible expression system
32
33 Potr*. This plasmid was integrated into the genome of *S. venezuelae* ISP5230 to drive
34
35 the expression of silent jadomycin BGC³⁷ (Fig. 6a). As expected, jadomycin B
36
37 production gradually increased with the OTC inducer (Fig. 6b), while the control
38
39 without OTC induction showed almost no production, similar to the results of wild
40
41 type *S. venezuelae* ISP5230. These results indicate that the inducible expression
42
43 system can be applied in the activation and identification of silent and possibly cryptic
44
45 natural products in streptomycetes.
46
47
48
49
50
51
52
53
54

55 To improve the production of jadomycin, the expression levels of jadomycin BGC
56
57
58
59
60

1
2
3
4 were optimized by adding different doses of OTC at different growth time points.
5
6 Accordingly, jadomycin B production under different induction conditions was
7
8 examined. It was found that an induction dose of 0.75 μM OTC and time of 4 h was
9
10 optimal (Fig. 6c). The use of an inducible expression system to optimize the
11
12 production levels of secondary metabolites in streptomycetes is a promising approach
13
14 for the improvement of antibiotics production. Previously, overexpression of BGCs or
15
16 activators through constitutive strong promoters is a preferred approach³⁸. A potential
17
18 disadvantage of these approaches is that the constitutive expression of BGCs leads to
19
20 the synthesis of the products at early growth stage, which could reduce the growth of
21
22 host cell and concomitantly decrease the overall production level³⁹. The strategy of
23
24 fine-tuning the expression of BGCs could coordinate the biomass growth and desired
25
26 product accumulation. Our results suggest that the inducible expression system Potr*
27
28 can be applied as an optimizing tool in rational engineering.
29
30
31
32
33
34
35
36

37 Overall, new genetic parts (repressor OtrR, operator *otrO* and promoter *otrBp*) were
38
39 identified and characterized *de novo*. They have been shown to fulfill the
40
41 requirements of inducible expression system. Then the synthetic inducible expression
42
43 system Potr* was developed using these genetic parts, and it showed tightly tunable
44
45 strength through the inducer OTC in streptomycetes. Potr* was also designed as a tool
46
47 to activate silent gene clusters and to optimize the production of secondary
48
49 metabolites. The present work suggests that the synthetic inducible expression system
50
51 Potr* will play important roles on fine-tuning gene expression in streptomycetes and
52
53 the newly characterized genetic parts will have potential to be used in the control of
54
55
56
57
58
59
60

1
2
3
4 gene expression and construction of genetic circuits in synthetic biology.
5
6

7 **Methods**

10 **Bacterial strains and culture conditions**

11
12 The strains and plasmids used in the present study are listed in Supplementary Table
13 S1. *E. coli* JM109 and DH5 α were used for cloning and bioluminescence assays,
14
15 respectively; BL21(DE3) was used for the recombinant expression of OtrR protein. *E.*
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
coli strains were grown in Luria-Bertani (LB) medium containing ampicillin (100
 $\mu\text{g/ml}$), hygromycin (50 $\mu\text{g/ml}$), kanamycin (25 $\mu\text{g/ml}$) or chloramphenicol (25 $\mu\text{g/ml}$)
when necessary. For spore preparations, *Streptomyces coelicolor* M1146⁴⁰,
Streptomyces albus J1074⁴¹, *Streptomyces rimosus* M4018³⁹ and their derivatives
were maintained on mannitol-soya flour (MS) agar plates⁷, while *Streptomyces*
venezuelae ISP5230, *S. venezuelae* WVR2006⁴² and its derivatives were grown on
maltose-yeast extract-malt extract (MYM) agar plates⁷. For DNA and total RNA
preparation, *S. rimosus* M4018 was grown in TSB medium³⁹. For GFP reporter
assays, the derivatives of *S. coelicolor* M1146 and *S. albus* J1074 were grown in
supplemented minimum medium (SMM)⁷, while the derivatives of *S. venezuelae*
WVR2006 were grown in MYM liquid medium.

49 **Construction of plasmids**

50
51
52 All primers used in the present study are listed in Supplementary Table S2. For the
53
54
55
56
57
58
59
60
construction of pET-OtrR, *otrR* was amplified from the genomic DNA of *S. rimosus*
4018 with primer pair OtrRF1/OtrRR1. The product was digested with NdeI/XhoI and

1
2
3
4 inserted into the corresponding sites of pET-23b. For the construction of pLux-otrBp,
5
6 *otrBp* was amplified from genomic DNA of *S. rimosus* 4018 with primer pair
7
8 PBF1/PBR1. The product was digested with BamHI/XhoI and inserted into the
9
10 corresponding sites of pCS26-Pac⁴³. For the construction of pOtrR, *otrR* was
11
12 amplified using the primer pair OtrRF2/OtrRR2, and a fragment of plasmid backbone
13
14 was amplified from pACYC184 using the primer pair 184F/184R. The two fragments
15
16 were assembled using the In-Fusion cloning kit (Clontech) to generate pOtrR. For the
17
18 construction of pIJ-Potr, a 637-bp fragment containing *otrR* and *otrBp* was amplified
19
20 from *S. rimosus* 4018 genomic DNA using the primer pair PBF2/PBR2, and
21
22 enzymatically assembled with pIJ8660::BsaI-sfgfp³⁵ digested by BsaI to generate
23
24 pIJ-Potr⁴⁴. To construct pIJ-Potr*, a fragment of plasmid backbone was amplified
25
26 from pIJ-Potr using the primer pair IJF2/IJR2 and subsequently self-ligated through
27
28 enzymatic assembly to generate pIJ-Potr*. For the construction of plug-and-play
29
30 plasmids, a fragment of the plasmid backbone was amplified from pIJ-Potr* using the
31
32 primer pair IJF3/IJR3 and subsequently self-ligated to remove the sequences of *attP*
33
34 and integrase gene to generate pIW. A fragment of plasmid backbone was amplified
35
36 from pIW using the primer pair IWF1/IWR1 to remove the *gfp* gene, followed by
37
38 self-ligation through enzymatic assembly to generate pIW01. For the construction of
39
40 pIW01-jad, 5'-partial *jadJ* was amplified from *S. venezuelae* ISP5230 genomic DNA
41
42 using the primer pair JF/JR, and a fragment of plasmid backbone was amplified from
43
44 pIW01 using the primer pair IWF/IWR. Subsequently, the two fragments were
45
46 enzymatically assembled to generate pIW01-jad.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Expression and purification of OtrR

The plasmid pET-OtrR was introduced into *E. coli* BL21 (DE3) for recombinant expression of OtrR. These proteins were purified as previously described ⁴⁵.

EMSA

A probe for *otrBp* was amplified using the primers PBF4/PBR4 (Table S2). The probe was incubated with varying concentrations of purified OtrR at 25°C for 30 min in 20 µl of buffer containing 20 mM Tris-base (pH 7.5), 2 mM dithiothreitol, 5 mM MgCl₂, 0.5 mg/ml calf BSA and 5% glycerol. After incubation and electrophoresis, the non-denaturing 4% polyacrylamide gels were stained with SYBR Gold Nucleic Acid Gel Stain (Invitrogen) for 30 min in TBE (89 mM Tris-base, 89 mM boric acid, and 1 mM EDTA, pH 8.0), and photographed under an ultraviolet trans-illuminator using Bio-Rad GelDoc XR.

Luciferase assays *in vivo* using Lux reporter systems

The plasmid pLux-otrBp and control pCS26-Pac ⁴³ were introduced into *E. coli* DH5α. Subsequently, pOtrR was introduced into DH5α harboring pLux-otrBp to examine the effects of OtrR on *otrBp*. For luciferase assays, approximately 10⁶ cells were inoculated into 5 ml of LB for 12 h. Then the bioluminescence of *E. coli* cultures was measured using an EnSpire Multimode Reader (PerkinElmer).

DNase I footprinting assay

DNase I footprinting assays were performed through fluorescent labeling and

1
2
3
4 capillary analyses⁴⁶. Briefly, DNA fragments were prepared through PCR using
5
6 fluorescence-labeled primers PBF5/PBR4. After purification from agarose gel, the
7
8 labeled DNA fragments (120 ng) and respective concentrations of proteins were
9
10 added to a final reaction volume of 50 μ l, and incubated at 25°C for 20 min. Then the
11
12 fragments were digested with DNase I (Promega) for 1 min at 25°C and terminated
13
14 using stop buffer (Promega). After phenol-chloroform extraction and ethanol
15
16 precipitation, the samples were loaded onto an Applied Biosystems 3730 DNA
17
18 genetic analyzer (Applied Biosystems) together with the internal-lane size standard
19
20 ROX-500 (Applied Biosystems). A dye primer-based sequencing kit (Thermo) was
21
22 used to precisely determine the sequences after aligning the results of the capillary
23
24 electrophoresis reactions. The electrophoregrams were subsequently analyzed with
25
26 the GeneMarker v1.8 software.
27
28
29
30
31
32

33 34 **Determination of TSS**

35
36
37 5'-RACE experiments were conducted to map the transcriptional start points of *otrBp*
38
39 according to the manufacturer's instructions (RLM-RACE kit, Ambion). The total
40
41 RNA was extracted from *S. rimosus* M4018. GSPB1 was used as special outer *otrB*
42
43 primer, and GSPB2 was used as special inner *otrB* primer, respectively.
44
45
46
47

48 **SPR assays**

49
50
51 The SPR assays were conducted using a Biacore 3000 System (GE Healthcare). The
52
53 experiments were performed in PBS buffer (9 mM PBS, pH 7.4, 1% DMSO and 0.05%
54
55 Tween 20) with a flow rate of 30 μ l/min at 25°C. The probe was obtained after
56
57
58
59
60

1
2
3
4 annealing the biotin-labeled forward primer SPRF and the unlabeled reverse primer
5
6 SPRR, and then immobilized on a streptavidin sensor chip. OtrR was diluted to
7
8 different concentrations in PBS buffer and subsequently injected. At the end of each
9
10 cycle, 0.4% SDS was used to regenerate the surface. The data fitting for the binding
11
12 model was conducted using BIA evaluation 4.1 software (GE Healthcare).
13
14
15

16 17 **Quantitative measurement of GFP fluorescence**

18
19
20 For *S. venezuelae*, 1 ml of the 24-h seed cultures of the recombinant strains was
21
22 inoculated into 50 ml of MYM medium for 6 h, then induced by different doses of
23
24 OTC for 18 h. 200- μ l aliquots of the cultures were washed twice with PBS (pH 7.2)
25
26 and re-suspended with 1ml PBS, then GFP fluorescence was detected (excitation at
27
28 485 nm; emission at 512 nm, Synergy H4 Multi-Mode Reader). All fluorescence
29
30 values were normalized to cell growth (OD₆₀₀). For *S. coelicolor* and *S. albus*,
31
32 approximately 2×10^8 spores were inoculated into 50 ml of SMM medium for 48 and
33
34 42 h, respectively. Subsequently, the cells were washed twice with PBS (pH 7.2). The
35
36 pellets were re-suspended in 1 ml R buffer (20 mM Tris-HCl, 0.5 M NaCl, and 10%
37
38 (v/v) glycerol, pH 7.4) and subjected to ultra-sonication to generate a cell extract³.
39
40
41 The fluorescence intensity was quantified after normalizing the fluorescence intensity
42
43 to the protein concentration in the 200- μ l sample³. Each value and error bar
44
45 represents the average and standard deviation of three experimental replicates,
46
47
48
49
50
51
52
53
54 respectively.

55 56 **Transcriptional analysis using RT-qPCR**

1
2
3
4 Total RNA was isolated from *Streptomyces* samples using a standard procedure⁷ at
5
6 the same time as GFP fluorescence assay. The RNA samples were then treated with
7
8 RNase-free DNase (Progenia) and checked by PCR to eliminate the possibility of
9
10 chromosomal DNA contamination. First-strand cDNA of *gfp* gene was performed
11
12 using a Superscript III first-strand Synthesis System (Invitrogen) with 500 ng of total
13
14 RNA according to the manufacturer's instructions. All cDNA synthesis reactions
15
16 included a replicate reaction without reverse transcriptase to ensure the complete
17
18 removal of contaminating DNA from the RNA samples. The primers of *gfp* and *hrdB*
19
20 are listed in Supplementary Table S2. RT-qPCR was performed using the ABI 7500
21
22 Detection System and SYBR Green PCR Master Mix (Applied Biosystems). The
23
24 results were analyzed using ABI 7500 software v2.0.1 and the relative expression
25
26 levels of the target genes were normalized to endogenous *hrdB* levels. All samples
27
28 were analyzed in triplicate.
29
30
31
32
33
34

35 36 **Activation of jadomycin BGC and optimization of jadomycin production**

37
38
39 The plasmid pIW01-jad was introduced into *E. coli* ET12567 (pUZ8002) and
40
41 conjugated into *S. venezuelae* ISP5230. Recombinant strains were incubated in 96
42
43 deep-well plates after the introduction of OTC at different time points and dose at
44
45 30°C with shaking (900 rpm), then the production of jadomycin B was examined. The
46
47 HPLC condition for the detection of jadomycin B was the same as previously
48
49 described⁴².
50
51
52
53
54

55 **Supporting Information Available**

56
57
58 Supplementary Figures, Tables and Sequences. This material is available free of
59
60

1
2
3
4 charge via the Internet at <http://pubs.acs.org>.

5
6
7 **Author information**

8
9 Corresponding Author

10
11 Keqian Yang. Email: yangkq@im.ac.cn; Address: State Key Laboratory of Microbial
12
13 Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101,
14
15 People's Republic of China.
16
17

18
19 Author Contributions

20
21
22 K.Y., W.W. and C.C. conceived the project. W.W., T.Y. and Y.L. performed the
23
24 experiment. S.L., S.Y., C.C. and K.S. assisted with the primary data analysis, W.W.,
25
26
27 K.Y. and C.C. wrote the manuscript.
28
29

30
31 Notes: The authors declare no competing interest.
32
33

34 **Acknowledgement**

35
36 This work was financially supported by grants from the National Natural Science
37
38 Foundation of China [Nos. 31400034 and 31570031], the Ministry of Science and
39
40 Technology of China [No. 2013CB734001] and the Beijing Natural Science
41
42 Foundation [No. 5154032]. W. W. is an awardee of Youth Innovation Promotion
43
44 Association of CAS [2016087].
45
46
47
48

49 **References**

- 50
51
52
53 1. Newman, D. J., and Cragg, G. M. (2012) Natural products as sources of new
54
55 drugs over the 30 years from 1981 to 2010, *J. Nat. Prod.* 75, 311-335.
56
57
58 2. Wang, W., Li, X., Wang, J., Xiang, S., Feng, X., and Yang, K. (2013) An
59
60

- 1
2
3
4 engineered strong promoter for streptomycetes, *Appl. Environ. Microbiol.* *79*,
5
6 4484-4492.
7
8
9 3. Li, S., Wang, J., Li, X., Yin, S., Wang, W., and Yang, K. (2015) Genome-wide
10
11 identification and evaluation of constitutive promoters in streptomycetes,
12
13 *Microb. Cell Fact.* *14*, 172.
14
15
16 4. Luo, Y., Zhang, L., Barton, K. W., and Zhao, H. (2015) Systematic
17
18 identification of a panel of strong constitutive promoters from *Streptomyces*
19
20 *albus*, *ACS Synth. Biol.* *4*, 1001-1010.
21
22
23
24 5. Medema, M. H., Breitling, R., and Takano, E. (2011) Synthetic biology in
25
26 *Streptomyces* bacteria, *Methods Enzymol.* *497*, 485-502.
27
28
29 6. Siegl, T., Tokovenko, B., Myronovskiy, M., and Luzhetskyy, A. (2013) Design,
30
31 construction and characterisation of a synthetic promoter library for fine-tuned
32
33 gene expression in actinomycetes, *Metab. Eng.* *19*, 98-106.
34
35
36 7. Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F., and Hopwood, D. A. (2000)
37
38 *Practical Streptomyces Genetics*, The John Innes Foundation, Norwich, UK.
39
40
41 8. Smanski, M. J., Zhou, H., Claesen, J., Shen, B., Fischbach, M. A., and Voigt, C.
42
43 A. (2016) Synthetic biology to access and expand nature's chemical diversity,
44
45 *Nat. Rev. Micro.* *14*, 135-149.
46
47
48
49 9. Terpe, K. (2006) Overview of bacterial expression systems for heterologous
50
51 protein production: from molecular and biochemical fundamentals to
52
53 commercial systems, *Appl. Microbiol. Biotechnol.* *72*, 211-222.
54
55
56
57 10. Heiss, S., Hormann, A., Tauer, C., Sonnleitner, M., Egger, E., Grabherr, R.,
58
59
60

- 1
2
3
4 and Heintl, S. (2016) Evaluation of novel inducible promoter/repressor systems
5
6 for recombinant protein expression in *Lactobacillus plantarum*, *Microb. Cell*
7
8 *Fact.* 15, 50.
- 9
10
11 11. Lan, E. I., and Liao, J. C. (2011) Metabolic engineering of cyanobacteria for
12
13 1-butanol production from carbon dioxide, *Metab. Eng.* 13, 353-363.
- 14
15
16 12. Martin, V. J., Pitera, D. J., Withers, S. T., Newman, J. D., and Keasling, J. D.
17
18 (2003) Engineering a mevalonate pathway in *Escherichia coli* for production
19
20 of terpenoids, *Nat. Biotechnol.* 21, 796-802.
- 21
22
23 13. Takano, E., White, J., Thompson, C. J., and Bibb, M. J. (1995) Construction
24
25 of thiostrepton-inducible, high-copy-number expression vectors for use in
26
27 *Streptomyces* spp, *Gene* 166, 133-137.
- 28
29
30
31 14. Ali, N., Herron, P. R., Evans, M. C., and Dyson, P. J. (2002) Osmotic
32
33 regulation of the *Streptomyces lividans* thiostrepton-inducible promoter, *ptipA*,
34
35 *Microbiology* 148, 381-390.
- 36
37
38 15. Murakami, T., Holt, T. G., and Thompson, C. J. (1989) Thiostrepton-induced
39
40 gene expression in *Streptomyces lividans*, *J. Bacteriol.* 171, 1459-1466.
- 41
42
43 16. Herai, S., Hashimoto, Y., Higashibata, H., Maseda, H., Ikeda, H., Omura, S.,
44
45 and Kobayashi, M. (2004) Hyper-inducible expression system for
46
47 streptomycetes, *Proc. Natl. Acad. Sci. U.S.A.* 101, 14031-14035.
- 48
49
50
51 17. Rodriguez-Garcia, A., Combes, P., Perez-Redondo, R., Smith, M. C., and
52
53 Smith, M. C. (2005) Natural and synthetic tetracycline-inducible promoters for
54
55 use in the antibiotic-producing bacteria *Streptomyces*, *Nucleic Acids Res.* 33,
56
57
58
59
60

- 1
2
3
4 e87.
5
6 18. Horbal, L., Fedorenko, V., and Luzhetskyy, A. (2014) Novel and tightly
7
8 regulated resorcinol and cumate-inducible expression systems for
9
10 *Streptomyces* and other actinobacteria, *Appl. Microbiol. Biotechnol.* 98,
11
12 8641-8655.
13
14
15
16 19. Davis, J. R., and Sello, J. K. (2010) Regulation of genes in *Streptomyces*
17
18 bacteria required for catabolism of lignin-derived aromatic compounds, *Appl.*
19
20 *Microbiol. Biotechnol.* 86, 921-929.
21
22
23
24 20. Romero-Rodriguez, A., Robledo-Casados, I., and Sanchez, S. (2015) An
25
26 overview on transcriptional regulators in *Streptomyces*, *Biochim. Biophys.*
27
28 *Acta.* 1849, 1017-1039.
29
30
31
32 21. Liu, G., Chater, K. F., Chandra, G., Niu, G., and Tan, H. (2013) Molecular
33
34 regulation of antibiotic biosynthesis in *Streptomyces*, *Microbiol. Mol. Biol. Rev.*
35
36 77, 112-143.
37
38
39 22. Tahlan, K., Ahn, S. K., Sing, A., Bodnaruk, T. D., Willems, A. R., Davidson,
40
41 A. R., and Nodwell, J. R. (2007) Initiation of actinorhodin export in
42
43 *Streptomyces coelicolor*, *Mol. Microbiol.* 63, 951-961.
44
45
46
47 23. Cuthbertson, L., and Nodwell, J. R. (2013) The TetR family of regulators,
48
49 *Microbiol. Mol. Biol. Rev.* 77, 440-475.
50
51
52 24. Ostash, I., Ostash, B., Luzhetskyy, A., Bechthold, A., Walker, S., and
53
54 Fedorenko, V. (2008) Coordination of export and glycosylation of
55
56 landomycins in *Streptomyces cyanogenus* S136, *FEMS Microbiol. Lett.* 285,
57
58
59
60

- 1
2
3
4 195-202.
5
6 25. Le, T. B., Schumacher, M. A., Lawson, D. M., Brennan, R. G., and Buttner, M.
7
8 J. (2011) The crystal structure of the TetR family transcriptional repressor
9
10 SimR bound to DNA and the role of a flexible N-terminal extension in minor
11
12 groove binding, *Nucleic Acids Res.* 39, 9433-9447.
13
14
15
16 26. Namwat, W., Lee, C. K., Kinoshita, H., Yamada, Y., and Nihira, T. (2001)
17
18 Identification of the *varR* gene as a transcriptional regulator of virginiamycin
19
20 S resistance in *Streptomyces virginiae*, *J. Bacteriol.* 183, 2025-2031.
21
22
23
24 27. Bertram, R., and Hillen, W. (2008) The application of Tet repressor in
25
26 prokaryotic gene regulation and expression, *Microb. Biotechnol.* 1, 2-16.
27
28
29 28. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H.
30
31 (1995) Transcriptional activation by tetracyclines in mammalian cells, *Science*
32
33 268, 1766-1769.
34
35
36 29. Stebbins, M. J., Urlinger, S., Byrne, G., Bello, B., Hillen, W., and Yin, J. C.
37
38 (2001) Tetracycline-inducible systems for *Drosophila*, *Proc. Natl. Acad. Sci.*
39
40 *U.S.A.* 98, 10775-10780.
41
42
43 30. Hertweck, C., Luzhetskyy, A., Rebets, Y., and Bechthold, A. (2007) Type II
44
45 polyketide synthases: gaining a deeper insight into enzymatic teamwork, *Nat.*
46
47 *Prod. Rep.* 24, 162-190.
48
49
50
51 31. Perera, I. C., and Grove, A. (2010) Molecular mechanisms of ligand-mediated
52
53 attenuation of DNA binding by MarR family transcriptional regulators, *J. Mol.*
54
55 *Cell. Biol.* 2, 243-254.
56
57
58
59
60

- 1
2
3
4 32. Strohl, W. R. (1992) Compilation and analysis of DNA sequences associated
5 with apparent streptomycete promoters, *Nucleic Acids Res.* 20, 961-974.
6
7
8
9 33. Pullan, S. T., Chandra, G., Bibb, M. J., and Merrick, M. (2011) Genome-wide
10 analysis of the role of GlnR in *Streptomyces venezuelae* provides new insights
11 into global nitrogen regulation in actinomycetes, *BMC Genomics* 12, 175.
12
13
14
15 34. Bibb, M. J., Janssen, G. R., and Ward, J. M. (1985) Cloning and analysis of
16 the promoter region of the erythromycin resistance gene (*ermE*) of
17 *Streptomyces erythraeus*, *Gene* 38, 215-226.
18
19
20
21
22 35. Bai, C., Zhang, Y., Zhao, X., Hu, Y., Xiang, S., Miao, J., Lou, C., and Zhang,
23 L. (2015) Exploiting a precise design of universal synthetic modular
24 regulatory elements to unlock the microbial natural products in *Streptomyces*,
25 *Proc. Natl. Acad. Sci. U.S.A.* 112, 12181-12186.
26
27
28
29
30
31
32 36. Zhang, F., Carothers, J. M., and Keasling, J. D. (2012) Design of a dynamic
33 sensor-regulator system for production of chemicals and fuels derived from
34 fatty acids, *Nat. Biotechnol.* 30, 354-359.
35
36
37
38
39
40
41 37. Doull, J., Singh, A., Hoare, M., and Ayer, S. (1994) Conditions for the
42 production of jadomycin B by *Streptomyces venezuelae* ISP5230: Effects of
43 heat shock, ethanol treatment and phage infection, *J. Ind. Microb.* 13,
44 120-125.
45
46
47
48
49
50
51 38. Hwang, K. S., Kim, H. U., Charusanti, P., Palsson, B. O., and Lee, S. Y. (2014)
52 Systems biology and biotechnology of *Streptomyces* species for the production
53 of secondary metabolites, *Biotechnol. Adv.* 32, 255-268.
54
55
56
57
58
59
60

- 1
2
3
4 39. Yin, S., Wang, W., Wang, X., Zhu, Y., Jia, X., Li, S., Yuan, F., Zhang, Y., and
5
6 Yang, K. (2015) Identification of a cluster-situated activator of oxytetracycline
7
8 biosynthesis and manipulation of its expression for improved oxytetracycline
9
10 production in *Streptomyces rimosus*, *Microb. Cell Fact.* 14, 46.
11
12
13
14 40. Gomez-Escribano, J. P., and Bibb, M. J. (2011) Engineering *Streptomyces*
15
16 *coelicolor* for heterologous expression of secondary metabolite gene clusters,
17
18 *Microb. Biotechnol.* 4, 207-215.
19
20
21 41. Chater, K. F., and Wilde, L. C. (1980) *Streptomyces albus* G mutants
22
23 defective in the SalGI restriction-modification system, *J. Gen. Microbiol.* 116,
24
25 323-334.
26
27
28 42. Fan, K., Pan, G., Peng, X., Zheng, J., Gao, W., Wang, J., Wang, W., Li, Y., and
29
30 Yang, K. (2012) Identification of JadG as the B ring opening oxygenase
31
32 catalyzing the oxidative C-C bond cleavage reaction in jadomycin
33
34 biosynthesis, *Chem. Biol.* 19, 1381-1390.
35
36
37
38 43. Bjarnason, J., Southward, C. M., and Surette, M. G. (2003) Genomic profiling
39
40 of iron-responsive genes in *Salmonella enterica* serovar typhimurium by
41
42 high-throughput screening of a random promoter library, *J. Bacteriol.* 185,
43
44 4973-4982.
45
46
47
48 44. Gibson, D. G., Young, L., Chuang, R. Y., Venter, J. C., Hutchison, C. A., 3rd,
49
50 and Smith, H. O. (2009) Enzymatic assembly of DNA molecules up to several
51
52 hundred kilobases, *Nat. Methods* 6, 343-345.
53
54
55
56 45. Wang, W., Li, X., Li, Y., Li, S., Fan, K., and Yang, K. (2015) A genetic
57
58
59
60

1
2
3 biosensor for identification of transcriptional repressors of target promoters,
4
5
6 *Sci. Rep.* 5, 15887.
7

- 8
9 46. Zianni, M., Tessanne, K., Merighi, M., Laguna, R., and Tabita, F. R. (2006)
10
11 Identification of the DNA bases of a DNase I footprint by the use of dye
12
13 primer sequencing on an automated capillary DNA analysis instrument, *J.*
14
15 *Biomol. Tech.* 17, 103-113.
16
17
18
19
20
21

22 **Figure legends and tables**

23
24
25 **Figure 1** Position and arrangement of *otrR* and *otrB* genes in the OTC BGC.
26
27

28 **Figure 2** Identification of the repression effect of OtrR and the de-repression effect of
29
30 OTC. **(a)** Schematic representation of the Lux reporter system. **(b)** OtrR represses the
31
32 bioluminescence controlled by *otrBp* and OTC induces the bioluminescence *in vivo*.
33
34 All values are presented in relative light units (RLU) and represented as the means \pm
35
36 SD from at least three independent experiments. **(c)** EMSA of the interaction between
37
38 the P-*otrB* and OtrR. Each lane contains 6 ng of P-*otrB* and different amounts of OtrR.
39
40
41
42 **(d)** Dissociation effect of the DNA-binding activity of OtrR in the presence of OTC.
43
44 Each lane contains 6 ng of P-*otrB*, 0.15 μ M OtrR and different amounts of OTC.
45
46
47

48
49 **Figure 3** Characterization of the interaction between the operator *otrO* and OtrR. **(a)**
50
51 Capillary electrophoregram of the DNase I digestion reaction of *otrBp* protected by
52
53 0.15 μ M OtrR. **(b)** Capillary electrophoregram of sequencing reactions of *otrBp*
54
55 aligned by GeneMarker v1.8 software. The sequence around the protected region is
56
57
58
59
60

1
2
3
4 indicated below the electrophoregrams, and the palindromic sequence of the protected
5
6 region is indicated with arrows. **(c)** SPR analysis of the equilibrium dissociation
7
8 constant (K_D) of the interaction between OtrR and *otrO*. **(d)** Nucleotide sequences of
9
10 the core region of *otrBp*. The transcriptional start site (TSS) is indicated with an
11
12 asterisk. The operator *otrO* characterized with inverted repeat sequences is indicated
13
14 with arrows. The presumptive -10 and -35 regions of *otrBp* are indicated with boxes.

15
16
17
18
19 **Figure 4** Development of the inducible expression system Potr*. **(a)** Expression
20
21 levels of Potr in response to different doses of OTC measured by GFP fluorescence.
22
23 The inducer concentrations were 0, 0.01, 0.02, 0.04, 0.08, 0.2, 0.4, 0.8, 1.6, 2, 3, 4, 5,
24
25 and 6 μM OTC. The values are presented as the means \pm SD of three independent
26
27 experiments. **(b)** Activity of the on and off state of Potr. 4 μM OTC was used to fully
28
29 induce the activity of Potr. **(c)** Core promoter sequences of the native Potr and the
30
31 developed Potr*. The TSS is indicated with an asterisk. The presumptive -10 and -35
32
33 regions are indicated with boxes, and the operator *otrO* is underlined. **(d)** Expression
34
35 levels of Potr* in response to different doses of OTC measured by GFP reporter. The
36
37 same OTC concentrations as in A were used. **(e)** Activity of the on and off state of
38
39 Potr*. 4 μM OTC was used to fully induce the activity.

40
41
42
43
44
45
46
47 **Figure 5** Evaluation of the performance of Potr* in different *Streptomyces* species. **(a)**
48
49 Quantitative analyses of the transcript levels of *gfp* controlled by Potr* in response to
50
51 OTC in *S. venezuelae*. The relative value of *gfp* transcript controlled by the
52
53 constitutive promoter *ermE** was arbitrarily assigned as one. **(b)** GFP fluorescence in
54
55 response to different doses of OTC in *S. coelicolor* M1146. **(c)** GFP fluorescence in
56
57
58
59
60

1
2
3
4 response to different doses of OTC in *S. albus* J1074. **(d)** Quantitative analyses of the
5
6 transcript level of *gfp* controlled by *Potr** in response to OTC in *S. coelicolor* M1146.
7
8 The relative value of *gfp* transcript controlled by *ermE** was arbitrarily assigned as
9
10 one. **(e)** Quantitative analyses of the transcript level of *gfp* in response to OTC in *S.*
11
12 *albus* J1074. The relative value of *gfp* transcript controlled by *ermE** was arbitrarily
13
14 assigned as one. For **a**, **b**, **c**, **d** and **e**, the values are presented as the means \pm SD of
15
16 three independent experiments and the control is a strain containing a plasmid
17
18 (pIJ8660::BsaI-sfgfp) with promoterless *gfp*.
19
20
21
22
23


24 **Figure 6** Application of *Potr** for the activation of the silent jadomycin BGC and the
25
26 optimization of jadomycin production. **(a)** Schematic representation of the strategy to
27
28 activate or optimize the expression of the jadomycin BGC. pIW01 is the plasmid
29
30 containing the inducible expression system *Potr** and the multiple cloning site (MCS)
31
32 for inserting the target fragment. **(b)** The activation and identification of the product
33
34 of silent jadomycin BGC through induction using gradient doses of OTC. **(c)** Heat
35
36 map showing the production of jadomycin B for all combinations of different OTC
37
38 doses and induction time points.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Pairs of antibiotic exporter and regulatory genes of in type II polyketide synthesis clusters.

<i>Streptomyces</i> species	Type II polyketide	Transporter	Regulator/family	Effector ^a	GenBank accession number
<i>S. coelicolor</i>	Actinorhodin	ActII-ORF2	ActII-ORF1/TetR family	(S)-DNPA; kalafungin	M64683
<i>S. sp.</i> CM020	Alnumycin	AlnT1	AlnR8/MarR family	NA	EU852062
<i>S. maritimus</i>	Enterocin	EncT	EncS/TetR family	NA	AF254925
<i>S. griseoflavus</i>	Gilvocarcin	GilJ	GilI/DeoR family	NA	AY233211
<i>S. cyanogenus</i>	Landomycin	LanJ	LanK/TetR family	landomycin A and B	AF080235
<i>S. glaucescens</i>	Tetracenomycin	TcmA	TcmR/TetR family	Tetracenomycin	M80674
<i>S. antibioticus</i>	Oviedomycin	OvmE	Orf3/ArsR family	NA	AJ632203
<i>S. rimosus</i>	Oxytetracycline	OtrB	OtrR/MarR family	NA	DQ143963
<i>S. aureofaciens</i>	Chlortetracycline	CtcR	CtcS/MarR family	NA	HM627755
<i>S. steffisburgensis</i>	Steffimycin	SfrB	StfRIII/MarR family	NA	AM156932
<i>S. fradiae</i> Tü2717	Urdamycin	UrdJ	UrdK/TetR family	NA	AF164961
<i>S. antibioticus</i>	Simocyclinone	SimX	SimR/TetR family	Simocyclinone D8 and C4	AF324838

^a NA indicate the unknown effector.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



25 Figure 1 Position and arrangement of *otrR* and *otrB* genes in the OTC BGC.
26 45x24mm (300 x 300 DPI)

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 Identification of the repression effect of OtrR and the de-repression effect of OTC. (a) Schematic representation of the Lux reporter system. (b) OtrR represses the bioluminescence controlled by *otrBp* and OTC induces the bioluminescence *in vivo*. All values are presented in relative light units (RLU) and represented as the means \pm SD from at least three independent experiments. (c) EMSA of the interaction between the P-*otrB* and OtrR. Each lane contains 6 ng of P-*otrB* and different amounts of OtrR. (d) Dissociation effect of the DNA-binding activity of OtrR in the presence of OTC. Each lane contains 6 ng of P-*otrB*, 0.15 μ M OtrR and different amounts of OTC.

123x86mm (300 x 300 DPI)




Figure 3 Characterization of the interaction between the operator *otrO* and OtrR. (a) Capillary electrophoregram of the DNase I digestion reaction of *otrBp* protected by 0.15 μM OtrR. (b) Capillary electrophoregram of sequencing reactions of *otrBp* aligned by GeneMarker v1.8 software. The sequence around the protected region is indicated below the electrophoregrams, and the palindromic sequence of the protected region is indicated with arrows. (c) SPR analysis of the equilibrium dissociation constant (K_D) of the interaction between OtrR and *otrO*. (d) Nucleotide sequences of the core region of *otrBp*. The transcriptional start site (TSS) is indicated with an asterisk. The operator *otrO* characterized with inverted repeat sequences is indicated with arrows. The presumptive -10 and -35 regions of *otrBp* are indicated with boxes.

161x309mm (300 x 300 DPI)




Figure 4 Development of the inducible expression system Potr*. (a) Expression levels of Potr in response to different doses of OTC measured by GFP fluorescence. The inducer concentrations were 0, 0.01, 0.02, 0.04, 0.08, 0.2, 0.4, 0.8, 1.6, 2, 3, 4, 5, and 6 μ M OTC. The values are presented as the means \pm SD of three independent experiments. (b) Activity of the on and off state of Potr. 4 μ M OTC was used to fully induce the activity of Potr. (c) Core promoter sequences of the native Potr and the developed Potr*. The TSS is indicated with an asterisk. The presumptive -10 and -35 regions are indicated with boxes, and the operator *otrO* is underlined. (d) Expression levels of Potr* in response to different doses of OTC measured by GFP reporter. The same OTC concentrations as in a were used. (e) Activity of the on and off state of Potr*. 4 μ M OTC was used to fully induce the activity of Potr*.

160x145mm (300 x 300 DPI)




Figure 5 Evaluation of the performance of Potr* in different *Streptomyces* species. (a) Quantitative analyses of the transcript levels of *gfp* controlled by Potr* in response to OTC in *S. venezuelae*. The relative value of *gfp* transcript controlled by the constitutive promoter *ermE** was arbitrarily assigned as one. (b) GFP fluorescence in response to different doses of OTC in *S. coelicolor* M1146. (c) GFP fluorescence in response to different doses of OTC in *S. albus* J1074. (d) Quantitative analyses of the transcript level of *gfp* controlled by Potr* in response to OTC in *S. coelicolor* M1146. The relative value of *gfp* transcript controlled by *ermE** was arbitrarily assigned as one. (e) Quantitative analyses of the transcript level of *gfp* in response to OTC in *S. albus* J1074. The relative value of *gfp* transcript controlled by *ermE** was arbitrarily assigned as one. For a, b, c, d and e, the values are presented as the means \pm SD of three independent experiments and the control is a strain containing a plasmid (pIJ8660::BsaI-sfgfp) with promoterless *gfp*.

189x202mm (300 x 300 DPI)





Figure 6 Application of Potr* for the activation of the silent jadomycin BGC and the optimization of jadomycin production. (a) Schematic representation of the strategy to activate or optimize the expression of the jadomycin BGC. pIW01 is the plasmid containing the inducible expression system Potr* and the multiple cloning site (MCS) for inserting the target fragment. (b) The activation and identification of the product of silent jadomycin BGC through induction using gradient doses of OTC. (c) Heat map showing the production of jadomycin B for all combinations of different OTC doses and induction time points.

153x137mm (300 x 300 DPI)



For Table of Contents Use Only

Title: "Development of a synthetic oxytetracycline-inducible expression system for streptomycetes using de novo characterized genetic parts"

Author(s): Wang, Weishan; Yang, Tongjian; Li, Yihong; Li, Shanshan; Yin, Shouliang; Styles, Kathryn ; Corre, Christophe; Yang, Keqian
35x15mm (300 x 300 DPI)